BriaCell Therapeutics (BCTX) vs Cel-Sci (CVM)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
BriaCell Therapeutics (BCTX) has outperformed Cel-Sci (CVM) over the past year, losing 69.2% versus a loss of 80.6%. Over five years, BCTX leads with a -95.2% price change compared with -99.4% for CVM. Cel-Sci is the larger company by market cap ($34.3 million vs $34.1 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BCTX | CVM |
|---|---|---|
| Share price | $3.92 | $1.95 |
| Market cap | $34.10M | $34.30M |
| 1-day change | -2.00% | -8.45% |
| YTD return | -44.87% | -62.93% |
| 1-year return | -69.18% | -80.56% |
| 5-year return | -95.21% | -99.38% |
| EPS (TTM) | $-0.92 | $-1.69 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $14.68 | $10.24 |
| 52-week low | $2.60 | $0.89 |
| Distance from 52-week high | -73.30% | -80.96% |
| Analyst consensus | — | none |
| Avg. price target upside | — | +541.03% |
| Average volume | 278.91K | 243.94K |
| Shares outstanding | 8.70M | 17.59M |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- BCTX has outperformed CVM by 11.4 percentage points over the past year.
About BriaCell Therapeutics
BCTX stock →BriaCell Therapeutics Corp., a pre-clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted immunotherapy program against end-stage breast cancer that is in Phase 3 clinical trials.
Health Care · Biotechnology: Pharmaceutical Preparations
About Cel-Sci
CVM stock →CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development to treat cancer and other diseases by using the immune system in the United States. The company's lead immunotherapy is Multikine, which has completed Phase III clinical trials for the potential treatment of certain head and neck cancers.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances)
BCTX vs CVM FAQ
Which is bigger, BriaCell Therapeutics or Cel-Sci?
Cel-Sci (CVM) is larger, with a market capitalization of $34.30M compared with $34.10M for BriaCell Therapeutics (BCTX).
Which stock has performed better over the past year, BCTX or CVM?
BCTX returned -69.18% over the past 12 months, compared with -80.56% for CVM (price return, excluding dividends). Past performance does not predict future results.
Are BriaCell Therapeutics and Cel-Sci in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Pharmaceutical Preparations for BriaCell Therapeutics and Biotechnology: Biological Products (No Diagnostic Substances) for Cel-Sci.